Patents by Inventor Inbar AMIT

Inbar AMIT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered anti-IL-2 antibodies
    Patent number: 12275784
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: April 15, 2025
    Assignee: AULOS BIOSCIENCE, INC.
    Inventors: Inbar Amit, Itay Levin, Guy Nimrod, Sharon Fischman, Reut Barak Fuchs, Marek Strajbl, Timothy Wyant, Michael Zhenin, Olga Bluvshtein Yermolaev, Yehezkel Sasson, Noam Grossman, Natalia Levitin, Yanay Ofran
  • ENGINEERED ANTI-IL-2 ANTIBODIES
    Publication number: 20240092888
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Application
    Filed: October 23, 2023
    Publication date: March 21, 2024
    Applicant: Aulos Bioscience, Inc
    Inventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
  • Engineered anti-IL-2 antibodies
    Patent number: 11851485
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: December 26, 2023
    Assignee: AULOS BIOSCIENCE, INC.
    Inventors: Inbar Amit, Itay Levin, Guy Nimrod, Sharon Fischman, Reut Barak Fuchs, Marek Strajbl, Timothy Wyant, Michael Zhenin, Olga Bluvshtein Yermolaev, Yehezkel Sasson, Noam Grossman, Natalia Levitin, Yanay Ofran
  • ENGINEERED ANTI-IL-2 ANTIBODIES
    Publication number: 20230203152
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Application
    Filed: November 16, 2022
    Publication date: June 29, 2023
    Applicant: Aulos Bioscience, Inc
    Inventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
  • ANTI-TUMOR NECROSIS FACTOR RECEPTOR (TNFR2) ANTIBODIES AND USES THEREOF
    Publication number: 20230167188
    Abstract: The present disclosure describes a number of anti-TNFR2 (tumor necrosis factor receptor 2) antibodies. These antibodies are TNFR2 agonists. In certain cases, these antibodies agonize TNFR2 in an Fc independent manner. These antibodies can modulate the proliferation and/or functions of regulatory T cells and myeloid-derived suppressor cells. In certain instances, these antibodies can be used to treat diseases such as GvHD or autoimmune diseases.
    Type: Application
    Filed: July 1, 2021
    Publication date: June 1, 2023
    Applicant: Biolojic Design Ltd.
    Inventors: Inbar AMIT, Itay LEVIN, Ayelet CHEN, Tal VANA, Nino OREN, Dor SAMET, Efrat CHOEN ZADA, Natalia LEVITIN, Guy NIMROD, Yehezkel SASSON, Alik DEMISHTEIN, Timothy WYANT, Reut BARAK FUCHS, Yair FASTMAN, Sharon FISCHMAN, Marek STRAJBL, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Noam GROSSMAN, Oshrat Shir TWITO, Nevet Zur BITON, Liron DANIELPUR, May Sofia BEN MAYOR, Yanay OFRAN
  • ENGINEERED ANTI-IL-2 ANTIBODIES
    Publication number: 20230085471
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Application
    Filed: February 15, 2021
    Publication date: March 16, 2023
    Applicant: Aulos Bioscience, Inc
    Inventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN